Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2017

View Archived Issues

miR-651 and miR-708 identified as serum biomarkers of renal cell carcinoma

Ebselen proves to be safe and effective in preventing noise-induced hearing loss in phase II study

Galantamine has beneficial effects in subjects with metabolic syndrome

Takeda Pharmaceutical presents novel mGluR7 agonists

Shanghai Institute of Organic Chemistry identifies novel IDO-1 inhibitors

Vitae Pharmaceuticals divulges new nuclear receptor ROR-gamma modulators

Novel apoptosis regulator Bcl-2 inhibitors patented by Newave Pharmaceutical

GlaxoSmithKline identifies novel ingenol derivatives

Luc Therapeutics initiates preclinical development in Ataxia program

Anti-TNF therapy corrects dysregulation of the Th17:Treg cell axis in hidradenitis suppurativa

Portola Pharmaceuticals is assigned a PDUFA date for the factor Xa inhibitor antidote andexanet

Takeda Pharmaceutical and Stanford University in partnership to accelerate therapeutic discoveries

Israel Innovation Authority grants USD 2 million to Biotime to develop OpRegen

Abbott extends tender offer for all outstanding shares of preferred stock of Alere

Lipocine's Tlando receives PDUFA date from the FDA

Regeneron plans to discontinue development of suptavumab for RSV

First patient treated in phase II trial of ONC-201 in neuroendocrine tumors

Soligenix receives additional NIAID funding for the development of heat stable ricin vaccine

HitGen enters collaboration agreement with Aduro Biotech

IND application accepted for glioblastoma multiforme immunotherapy VBI-1901

Shuttle Pharmaceuticals and POLA Pharma enter agreement to licence U.S. rights to doranidazole

Cerecor sells rights to CERC-501 to Janssen Pharmaceuticals

NIH awards millions to pediatric cancer research collective

Evotec announces completion of acquisition of Aptuit

Phase III study of Fovista in wet age-related macular degeneration does not meet primary endpoint

Bristol-Myers Squibb announces topline data from CheckMate214 phase III study

Zynerba Pharmaceuticals presents phase II results for ZYN-002

Amarin continues the REDUCE-IT cardiovascular outcomes study of Vascepa as planned

Fortress Biotech launches a new subsidiary to develop gene therapy

FDA removes clinical hold on phase III trial of Multikine in head and neck cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...